Advertisement

Search Results

Advertisement



Your search for The A matches 21900 pages

Showing 1 - 50


lymphoma
immunotherapy

Newer Therapeutic Approaches Improving Outcomes in Hodgkin Lymphoma

At the 2020 Debates and Didactics in Hematology and Oncology Virtual Conference, sponsored by Emory University School of Medicine and Winship Cancer Institute, Pamela Allen, MD, Assistant Professor of Medicine at Emory, described recent trials on therapeutic approaches that are informative on this...

colorectal cancer
geriatric oncology

Elderly Patients With Advanced Colorectal Cancer Treated With Adjuvant Oxaliplatin Plus Fluoropyrimidines: Tolerability and Benefit

Among patients with stage III colon cancer, patients aged 70 or older were less tolerant of adjuvant oxaliplatin/flouropyrimidine therapy, in addition to having poorer relapse-free interval rates on the regimen, according to findings from a large subgroup analysis of the phase III TOSCA trial...

genomics/genetics
immunotherapy

Nivolumab Shows Activity in edPOLE-Mutated, MMR-Proficient Advanced Cancers

Nivolumab monotherapy showed high response and disease control rates in patients with pathogenic exonuclease domain POLE (edPOLE)-mutated, mismatch repair (MMR)-proficient advanced tumors containing confirmed pathogenic mutations, according to findings presented by Benoit J.C. Rousseau, MD, PhD, of ...

lung cancer
immunotherapy

Continuous vs Fixed-Duration Immunotherapy in Previously Treated Patients With Advanced NSCLC

In an exploratory analysis of the phase IIIb/IV CheckMate 153 trial published in the Journal of Clinical Oncology, David M. Waterhouse, MD, MPH, and colleagues found that continuing nivolumab beyond 1 year of treatment vs stopping at 1 year of treatment was associated with better outcomes in...

breast cancer
genomics/genetics

Use of ctDNA to Direct Therapy in Advanced Breast Cancer

In the phase IIa plasmaMATCH platform trial reported in The Lancet Oncology, Nicholas C. Turner, MD, and colleagues found that circulating tumor DNA (ctDNA) provided accurate genotyping that permitted selection of directed therapies in patients with advanced breast cancer. Study Details The...

issues in oncology
legislation
health-care policy
covid-19

AACR Releases 10th Edition of Annual Cancer Progress Report

The American Association for Cancer Research (AACR) has released the 10th edition of its annual Cancer Progress Report. The report highlights how cancer research, largely supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI), is...

pancreatic cancer

Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer

The challenge in treating patients with borderline resectable pancreatic cancer is how to render tumors resectable and how to achieve the negative surgical margins that enhance long-term survival odds. Fortunately, neoadjuvant chemotherapy is helping to achieve these important goals, according to...

skin cancer
immunotherapy

Adjuvant Nivolumab vs Ipilimumab in Resected Advanced Melanoma: Long-Term Follow-up of CheckMate 238

Long-term findings from the phase III CheckMate 238 study showed that nivolumab improved 4-year recurrence-free survival compared with ipilimumab in patients with resected stage IIIB to C or IV melanoma in the overall population as well as across subgroups of patients stratified by disease stage...

gynecologic cancers

Does Radical Hysterectomy Improve Survival in Patients With Cervical Cancer and Intraoperative Detection of Positive Lymph Nodes?

No significant difference was observed in the risk of recurrence, local recurrence, or death between patients with cervical cancer in whom a radical uterine procedure (mostly radical hysterectomy) was completed or abandoned upon intraoperative detection of positive pelvic lymph nodes. These...

lung cancer

Study Examines Combined Impact of Aspirin, Metformin, and Statins on Lung Cancer Risk

Combined use of aspirin, metformin, and statins may be associated with decreased lung cancer incidence and mortality, according to a study published by Kang et al in the Journal of Thoracic Oncology. Study Methods The aim of this study was to investigate the associations of the three agents with...

breast cancer

Abbreviated Breast MRI as Supplementary Screening Method in Women With Dense Breasts

In a single-institution retrospective analysis reported in the Journal of Clinical Oncology, Weinstein et al identified the prevalent cancer detection rate associated with supplemental abbreviated breast magnetic resonance imaging (MRI) screening among average-risk women with dense breasts who had...

solid tumors
immunotherapy

Association of Tumor Mutational Burden With Response to Pembrolizumab in Previously Treated Patients With Advanced Solid Tumors

A prospective biomarker analysis of the multicohort phase II KEYNOTE-158 trial reported by Marabelle et al in The Lancet Oncology found that patients with previously treated advanced solid tumors were more likely to respond to pembrolizumab monotherapy if they had high tissue tumor mutational...

bladder cancer
immunotherapy

Early-Phase Trial Explores Cabozantinib and Nivolumab With or Without Ipilimumab in Advanced Genitourinary Malignancies

In a phase I trial reported in the Journal of Clinical Oncology, Andrea B. Apolo, MD, and colleagues found that the combination of cabozantinib and nivolumab, as well as the combination of cabozantinib/nivolumab plus ipilimumab, produced durable responses in patients with metastatic urothelial...

skin cancer
immunotherapy

Paolo A. Ascierto, MD, on Melanoma: Sequencing Targeted Treatments and Immunotherapy

Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori, discusses phase II results on progression-free survival for patients with advanced melanoma in the SECOMBIT study, whose aim is to evaluate the different sequencing of a BRAF inhibitor (encorafenib) plus a MEK inhibitor (binimetinib) with...

colorectal cancer
immunotherapy

Thierry Andre, MD, on Colorectal Cancer: Health-Related Quality of Life With Pembrolizumab vs Chemotherapy

Thierry Andre, MD, of Hôpital Saint-Antoine, discusses phase III KEYNOTE-177 findings on the reduced risk of disease progression or death in patients receiving pembrolizumab monotherapy as a first-line treatment of microsatellite instability–high and/or mismatch repair–deficient metastatic...

covid-19

Joint Statement From the AMA, AHA, and ANA on U.S. Coronavirus Death Toll

Today, the American Medical Association (AMA), American Hospital Association (AHA), and American Nurses Association (ANA) released a joint statement on the amount of deaths caused by the coronavirus in the United States. Today we mark a somber milestone as more than 200,000 people in the United...

gynecologic cancers

SOLO1 5-Year Follow-up: Maintenance Olaparib for BRCA-Mutated Advanced Ovarian Cancer

Almost half of patients who received the PARP inhibitor olaparib for newly diagnosed BRCA-mutated advanced ovarian cancer remained disease-free after 5 years, according to data presented by Susana Banerjee, MBBS, PhD, and colleagues during the ESMO Virtual Congress 2020 (Abstract 811MO). Patients...

prostate cancer

Overall Survival With Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer: Analysis From the SPARTAN Trial

As reported in European Urology by Matthew R. Smith, MD, and colleagues, the final analysis of phase III SPARTAN trial has shown significant prolongation of overall survival with apalutamide vs placebo in patients with nonmetastatic castration-resistant prostate cancer and prostate-specific antigen ...

colorectal cancer

Is Drinking Coffee Daily Linked to Improved Survival in Patients With Advanced Colorectal Cancer?

In a large group of patients with metastatic colorectal cancer, consumption of a few cups of coffee a day was associated with longer survival and reduced risk of disease progression, according to findings reported by Mackintosh et al in JAMA Oncology. The findings, based on data from a large...

supportive care
symptom management

Olanzapine for Children and Adolescents Receiving Highly Emetogenic Chemotherapy

In a single-center Indian phase III trial reported in the Journal of Clinical Oncology, Naik et al found that the addition of olanzapine to standard antiemetic treatment significantly increased the rate of complete response (CR; defined as no vomiting or use of rescue medication) among children and ...

breast cancer

Impact of Neoadjuvant Endocrine Therapy and Neoadjuvant Chemotherapy on Rates of Breast‑Conserving Surgery

“Studies that have compared neoadjuvant endocrine therapy with neoadjuvant chemotherapy have shown low pathologic complete response rates with both approaches. However, the rates of breast-conserving surgery have been shown to be slightly higher with neoadjuvant endocrine therapy,” Kelly Hunt, MD,...

kidney cancer
immunotherapy

Sumanta K. Pal, MD, on Renal Cell Carcinoma: Cabozantinib Plus Atezolizumab as First-Line Therapy

Sumanta K. Pal, MD, of the City of Hope National Medical Center, discusses results from the COSMIC-021 study, which tested two different doses of cabozantinib, each with a standard dose of atezolizumab, administered to patients with metastatic advanced clear cell renal cell carcinoma. Dr. Pal...

issues in oncology

New Report Focuses on Cancer Statistics in Adolescents and Young Adults

A new report examining cancer in adolescents and young adults (AYAs, defined as diagnoses occurring between the ages of 15 and 39) provides updated estimates of the contemporary cancer burden in this age group, with predictions that 89,500 cases and 9,270 deaths will occur in this group in 2020 in...

gastroesophageal cancer
immunotherapy

First-Line Checkpoint Inhibitors May Improve Survival in Gastroesophageal Cancers

Immune therapy for advanced gastroesophageal cancer has taken a leap forward by showing its value in the first-line setting, according to two studies in which nivolumab and pembrolizumab, both given with chemotherapy, significantly improved overall survival vs chemotherapy alone. The studies,...

sarcoma

Surgery With or Without Preoperative Radiotherapy for Primary Retroperitoneal Sarcoma

As reported in The Lancet Oncology by Bonvalot et al, the phase III EORTC-62092 (STRASS) trial showed that the addition of preoperative radiotherapy to surgery did not improve abdominal recurrence–free survival in patients with primary retroperitoneal sarcoma. Study Details In the open-label trial, ...

prostate cancer

Overall Survival Analysis From PROfound Trial: Olaparib for Metastatic Castration-Resistant Prostate Cancer

As reported in The New England Journal of Medicine and during the ESMO Virtual Congress 2020 (Abstract 610O) by Maha Hussain, MD, FACP, FASCO, and colleagues, an overall survival analysis from the phase III PROfound trial has shown a significant benefit with olaparib vs physician’s choice of...

lung cancer

David S. Hong, MD, on NSCLC: Durability of Clinical Benefit and Biomarkers in Patients Treated With Sotorasib

David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings on sotorasib, a novel, first-in-class, oral KRASG12C inhibitor. The agent demonstrated durable disease control in heavily pretreated patients with non–small cell lung cancer (Abstract 1257O).

breast cancer

Abemaciclib Plus Endocrine Therapy May Reduce Recurrence in Early Breast Cancer: monarchE Trial

For the first time, an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) has improved outcomes in patients with early breast cancer when combined with standard endocrine therapy, Stephen Johnston, MD, and colleagues reported at the ESMO Virtual Congress 2020 (Abstract LBA5_PR). Abemaciclib...

lung cancer

Study Questions Role of Routine Postoperative Radiotherapy in NSCLC With Mediastinal Nodes

The Lung ART trial was designed to demonstrate whether there was any benefit to the routine use of modern mediastinal postoperative radiotherapy in patients with non–small cell lung cancer (NSCLC) following complete resection and (neo)adjuvant chemotherapy. No difference in disease-free survival...

gynecologic cancers

World Gynecologic Oncology Awareness Day (World GO Day): September 20

Patient advocates and medical professionals in more than 20 countries have come together for the second annual World Gynecologic Oncology Day (World GO Day), taking place today, September 20. A project of the European Society of Gynaecological Oncology (ESGO) and the European Network of...

solid tumors
lung cancer

KRAS G12C Inhibitor Shows Activity in Solid Tumors, Lung Cancer

In a phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRAS G12C inhibitor sotorasib (AMG 510) showed manageable toxicities and durable clinical benefits. Results from the trial were published in The New England Journal of Medicine, and data from the ...

lung cancer

Masahiro Tsuboi, MD, on NSCLC: Adjuvant Osimertinib in EGFR-Mutated Disease

Masahiro Tsuboi, MD, of Japan’s National Cancer Center Hospital East, discusses the phase III results from the ADAURA study, which showed a reduced risk of local and distant recurrence in patients with resected EGFR-mutated non–small cell lung cancer, reinforcing adjuvant osimertinib as an...

kidney cancer
immunotherapy

Toni K. Choueiri, MD, on RCC: Nivolumab Plus Cabozantinib vs Sunitinib in First-Line Treatment

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses the first results from the phase III CheckMate 9ER trial, which suggested the combination of nivolumab and cabozantinib is safe. It showed activity in progression-free and overall survival, as well as in overall response rates and may ...

covid-19

Cancer Treatment–Related Outcomes in Patients With Cancer and COVID-19

Researchers have found that certain treatments for cancer may increase the chance of death if they contract COVID-19. These findings from a multicenter study presented by Trisha Wise-Draper, MD, and colleagues at the ESMO Virtual Congress 2020 (LBA71), shed light on ways standard anticancer...

kidney cancer
immunotherapy

CheckMate 9ER Trial Shows Benefit of Novel Doublet for Advanced Kidney Cancer

The combination of nivolumab plus cabozantinib was superior to the former standard, sunitinib, as first-line treatment for advanced/metastatic renal cell carcinoma, according to results of the phase III CheckMate 9ER trial reported by Toni K. Choueiri, MD, and colleagues at the ESMO Virtual...

bladder cancer
immunotherapy

Maintenance Avelumab Plus Best Supportive Care in Advanced Bladder Cancer

Findings from the JAVELIN Bladder 100 trial were published by Thomas Powles, MD, and colleagues in The New England Journal of Medicine. Researchers reported that the PD-L1 inhibitor avelumab led to a 31% reduction in risk of death, and extended median survival by more than 7 months in patients with ...

covid-19

Effects of the COVID-19 Pandemic on Cancer Care, Provider Well-Being

Delays and cancellation of cancer treatments and other safety measures undertaken to minimize the risk of exposure to the coronavirus have generated a backlog in oncology care and research. The threat of delayed diagnoses looms while oncology professionals face burnout, according to new studies...

issues in oncology

ESMO 2020: Access to Treatments and Trials Varies Widely for Patients With Cancer Across Europe

Access to cancer treatments is highly unequal across Europe, both for new drugs in development (due to disparities in access to clinical trials) and for currently approved drugs (due to disparities in health-care spending by different countries), according to results from two studies being...

prostate cancer
cns cancers
leukemia

FDA Pipeline: Designations in Prostate Cancer, Glioblastoma, and Pediatric Leukemia

Recently, the U.S. Food and Drug Administration (FDA) granted designations to agents for metastatic castration-resistant prostate cancer, recurrent glioblastoma, and pediatric acute myeloid leukemia. Fast Track Designation for EPI-7386 in Metastatic Castration-Resistant Prostate Cancer The FDA...

prostate cancer

Role of F-18–NaF PET/CT in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide

In a phase II study reported in the Journal of Clinical Oncology, Kyriakopoulos et al found that use of quantitative total bone imaging with fluorine-18 (F-18)–sodium fluoride (NaF) positron-emission tomography/computed tomography (PET/CT) helped identify heterogeneity of response in bone lesions...

breast cancer
immunotherapy

Addition of Pembrolizumab to Eribulin in HR-Positive, HER2-Negative Metastatic Breast Cancer

In a phase II trial reported in JAMA Oncology, Sara M. Tolaney, MD, MPH, and colleagues found that the addition of pembrolizumab to eribulin did not improve progression-free survival in women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer. As stated by the...

gastroesophageal cancer
gastrointestinal cancer
immunotherapy

First-Line PD-1 Inhibitor With or Without Chemotherapy vs Chemotherapy Alone in Advanced Gastric Cancer: KEYNOTE-062

As reported in JAMA Oncology by Kohei Shitara, MD, and colleagues, the phase III KEYNOTE-062 trial showed no significant improvement in overall or progression-free survival with first-line pembrolizumab with or without chemotherapy vs chemotherapy alone in patients with PD-L1–positive advanced...

issues in oncology

Caring for Undocumented Patients With Cancer

There are approximately 25 million foreign-born immigrants living in the United States, which is more than 13% of the nation’s total population. Of these individuals, it is estimated that about 11 million are undocumented; by far, the largest group of this immigrant undocumented population is...

covid-19

Viral Load May Help Predict Mortality Rate in Hospitalized Patients With Cancer and COVID-19

Higher viral loads may be associated with a greater risk of death among patients with cancer—and individuals without cancer—hospitalized with COVID-19, according to a report by Westblade et al in Cancer Cell. Among hospitalized patients infected with COVID-19, those with hematologic malignancies...

bladder cancer
immunotherapy

Proton Pump Inhibitor Use May Be Associated With Worse Outcomes in Patients Treated With Atezolizumab for Urothelial Cancer

Recent evidence indicates that proton pump inhibitors may cause significant changes in the gut microbiota; gut microbiota dysbiosis has been linked to reduced immune checkpoint inhibitor effectiveness. In a retrospective analysis of clinical trials investigating the immune checkpoint inhibitor...

pancreatic cancer

Adjuvant Chemotherapy After Pancreatic Cancer Resection and Neoadjuvant FOLFIRINOX: Improvement in Overall Survival?

In a retrospective cohort study reported in JAMA Oncology, van Roessel et al found that adjuvant chemotherapy after pancreatic cancer resection and neoadjuvant FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin) was associated with an improvement in overall survival. The benefit was...

issues in oncology

Effect of Machine Learning–Directed Clinical Evaluations on Acute Care Visits During Outpatient Therapy

In a single-institution study reported in the Journal of Clinical Oncology, Hong et al found that mandatory twice-weekly evaluations reduced the need for unplanned acute care visits among patients undergoing outpatient radiotherapy or chemoradiation who were identified as being at high risk for...

pancreatic cancer

Researchers Report on Comprehensive Analysis of Adenosquamous Carcinoma of the Pancreas

In a comprehensive analysis of adenosquamous cancer of the pancreas in preclinical models, researchers identified potential therapeutic targets for this aggressive form of pancreatic cancer. They also identified already-available agents—designed to treat other types of cancer—that may be useful in...

issues in oncology

Inaugural AACR Cancer Disparities Progress Report Released

The American Association for Cancer Research (AACR) released its inaugural Cancer Disparities Progress Report 2020, which found that while overall cancer death rates are declining and the number of survivors is reaching record highs, progress against cancer is not benefiting everyone equally, with...

prostate cancer

Overall Survival With Darolutamide in Patients With Nonmetastatic, Castration-Resistant Prostate Cancer: ARAMIS Trial

As reported in The New England Journal of Medicine by Karim Fizazi, MD, and colleagues, the phase III ARAMIS trial has shown significantly prolonged overall survival with darolutamide vs placebo in men with nonmetastatic castration-resistant prostate cancer. The previously reported primary analysis ...

Advertisement

Advertisement



Advertisement